• What are the biggest hurdles in moving from 21 CFR 212 to 210/211 compliance, and how can they be addressed?

• How are CDMOs/CMOs adapting their facilities and operations to meet late-phase and commercial needs?

• What role should radiopharmacies and compounding pharmacies play as products transition to broader commercialization?